Importantly, the results of the present study indicate, that co-inhibitory ICMs other than PD-L1, specifically LAG-3 and TIM-3, are also prominent in early BC patients following implementation of NAC and should therefore be considered as potential targets for future investigation in these patients as an adjunctive strategy to improve outcomes. The gene discussed is LAG3; the disease is breast cancer.